Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sweta Desai"'
Autor:
Ethan McClain, Sweta Desai, Amanda F. Cashen, Mark P. Foster, Peter Westervelt, Patrick Soon-Shiong, Michelle Becker-Hapak, Keith Stockerl-Goldstein, Jeffrey S. Miller, Miriam T. Jacobs, Mark A. Schroeder, Pamela Wong, Camille N. Abboud, Patrick Pence, Geoffrey L. Uy, Feng Gao, Claudio G. Brunstein, Melissa M. Berrien-Elliott, Meagan A. Jacoby, Iskra Pusic, Sarah Cooley, John F. DiPersio, Todd A. Fehniger
Publikováno v:
Blood. 139:1177-1183
Natural killer (NK) cells are a promising alternative to T cells for cancer immunotherapy. Adoptive therapies with allogeneic, cytokine-activated NK cells are being investigated in clinical trials. However, the optimal cytokine support after adoptive
Autor:
Pamela Wong, Jin-An Jiao, Timothy Schappe, Gilles M. Leclerc, Sweta Desai, Gabriela J. Muniz, Melissa M. Berrien-Elliott, Mark P. Foster, Lynne Marsala, Pallavi Chaturvedi, Carly Neal, Niraj Shrestha, Christian A. Echeverri, Xiaoyun Zhu, David A. Russler-Germain, Caitlin A. Prendes, Catherine M. Spanoudis, Todd A. Fehniger, Ethan McClain, Jack O. Egan, Michael J. Dee, Peter R. Rhode, Hing C. Wong, Jennifer Tran, Laritza L. Ramirez, Ryan P. Sullivan, Lijing You, Victor L. Gallo, Julia A. Wagner, Emily K. Jeng, Michelle Becker-Hapak, Patrick Pence
Publikováno v:
Cancer Immunol Res
Natural killer (NK) cells are a promising cellular therapy for cancer, with challenges in the field including persistence, functional activity, and tumor recognition. Briefly, priming blood NK cells with recombinant human (rh)IL-12, rhIL-15, and rhIL
Autor:
Amanda F. Cashen, Matthew L. Cooper, Carly Neal, Camille N. Abboud, Feng Gao, Sweta Desai, Melissa M. Berrien-Elliott, Michelle Becker-Hapak, Celia C. Cubitt, Timothy Schappe, Pamela Wong, Mark A. Schroeder, John F. DiPersio, Peter Westervelt, Julia A. Wagner, Jennifer A. Foltz, Meagan A. Jacoby, Natalia Jaeger, Iskra Pusic, Mark P. Foster, Geoffrey L. Uy, Todd A. Fehniger, Ethan McClain, Rizwan Romee, Keith Stockerl-Goldstein, Sridhar Nonavinkere Srivatsan
Publikováno v:
Cancer Discov
Natural killer (NK) cells are an emerging cancer cellular therapy and potent mediators of antitumor immunity. Cytokine-induced memory-like (ML) NK cellular therapy is safe and induces remissions in patients with acute myeloid leukemia (AML). However,
Autor:
Mark P. Foster, Rong Cai, Ana Karen Nunez Cortes, Yago Nieto, Vakul Mohanty, Melissa M. Berrien-Elliott, Sweta Desai, Joachim Koch, Michelle Becker-Hapak, Mecit Kaplan, Pamela Wong, May Daher, Natalie W. Fowlkes, Martin Treder, Luciana Garcia Melo, Wolfgang Fischer, Vandana Nandivada, Carly Neal, Luis Muniz-Feliciano, Li Li, Sonny Ang, Natalia Baran, Enli Liu, Elizabeth J. Shpall, Todd A. Fehniger, Yifei Shen, Richard E. Champlin, Ethan McClain, Mayela Mendt, Pinaki P. Banerjee, Francesca Lorraine Wei Inng Lim, Mayra Hernandez Sanabria, Oswaldo Keith Okamoto, Hila Shaim, Lucila Nassif Kerbauy, Katy Rezvani, Nancy D. Marin, Rafet Basar, Timothy Schappe, Ken Chen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Natural killer (NK) cells are a nascent cellular immunotherapy for hematologic malignancies. Target recognition of NK cell-resistant cancers remains a substantial barrier to broad application of NK cell therapy. One solution are bispecific